HURA Key Statistics, Chart & Performance
The current stock price of HURA is 0.7545 USD. In the past month the price decreased by -35.9%. In the past year, price decreased by -84.54%.
HURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About HURA
Company Profile
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Company Info
TUHURA BIOSCIENCES INC
10500 University Center Dr., Suite 110
Tampa FLORIDA US
Employees: 19
Phone: 18138756600
TUHURA BIOSCIENCES INC / HURA FAQ
What does HURA do?
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
What is the current price of HURA stock?
The current stock price of HURA is 0.7545 USD. The price increased by 0.99% in the last trading session.
What is the dividend status of TUHURA BIOSCIENCES INC?
HURA does not pay a dividend.
How is the ChartMill rating for TUHURA BIOSCIENCES INC?
HURA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of TUHURA BIOSCIENCES INC (HURA) based on its PE ratio?
TUHURA BIOSCIENCES INC (HURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.6).
What is TUHURA BIOSCIENCES INC worth?
TUHURA BIOSCIENCES INC (HURA) has a market capitalization of 38.68M USD. This makes HURA a Nano Cap stock.
HURA Technical Analysis
HURA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HURA. HURA has a bad profitability rating. Also its financial health evaluation is rather negative.
HURA Financial Highlights
Over the last trailing twelve months HURA reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS increased by 65.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -170.33% | ||
| ROE | -260.88% | ||
| Debt/Equity | 0.03 |
HURA Forecast & Estimates
9 analysts have analysed HURA and the average price target is 9.75 USD. This implies a price increase of 1192.74% is expected in the next year compared to the current price of 0.7545.